Scholarlink

Background <p>We aimed to evaluate the clinical utility of the LM1010 high-performance liquid chromatography with ultraviolet-visible detection instrument for measuring plasma concentrations of voriconazole (VRCZ) under routine clinical conditions, including in patients with diverse clinical backgrounds.</p> Methods <p>In total, 213 samples were collected from two hospitals (groups A and B). The plasma samples were analyzed using LM1010 and ultra performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS). Laboratory test values and information on concomitant medications were collected from electronic medical records.</p> Results <p>In total, 66 samples from group A and 135 samples from group B were included in the analysis.　Passing–Bablok regression analysis showed that in group A (<i>n</i> = 66), the slope was 0.972 (95% confidence interval [CI], 0.929–1.000) and the intercept −0.024 (95% CI, −0.100–0.056), indicating no significant proportional or constant bias. In group B (<i>n</i> = 135), the slope was 0.956 (95% CI, 0.930–0.975) and the intercept −0.006 (95% CI, −0.053–0.025), indicating a slight proportional bias but no constant bias. The Bland–Altman analysis demonstrated proportional bias in both groups A and B, and the slopes of the regression lines were 0.045 (95% CI, 0.011–0.079) and 0.038 (95% CI, 0.025–0.052), respectively. Interfering peaks were observed in the chromatograms of eight samples in group B, but their effect on the intermethod difference was small. No clinical laboratory test values or concomitant medications were identified as factors affecting the intermethod difference.</p> Conclusions <p>The measurement of VRCZ plasma concentration by LM1010 was robust under heterogeneous clinical conditions and was useful for clinical therapeutic drug monitoring of VRCZ.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of an HPLC-UV system (LM1010) and UPLC-MS/MS for plasma voriconazole measurement in routine clinical practice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Junichi Nakagawa,
  • Kayo Ueno,
  • Katsuyoshi Osanai,
  • Masahiro Ishiyama,
  • Miyuki Matsushita,
  • Satoru Morikawa,
  • Hirofumi Tomita,
  • Takenori Niioka

摘要

Background

We aimed to evaluate the clinical utility of the LM1010 high-performance liquid chromatography with ultraviolet-visible detection instrument for measuring plasma concentrations of voriconazole (VRCZ) under routine clinical conditions, including in patients with diverse clinical backgrounds.

Methods

In total, 213 samples were collected from two hospitals (groups A and B). The plasma samples were analyzed using LM1010 and ultra performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS). Laboratory test values and information on concomitant medications were collected from electronic medical records.

Results

In total, 66 samples from group A and 135 samples from group B were included in the analysis.　Passing–Bablok regression analysis showed that in group A (n = 66), the slope was 0.972 (95% confidence interval [CI], 0.929–1.000) and the intercept −0.024 (95% CI, −0.100–0.056), indicating no significant proportional or constant bias. In group B (n = 135), the slope was 0.956 (95% CI, 0.930–0.975) and the intercept −0.006 (95% CI, −0.053–0.025), indicating a slight proportional bias but no constant bias. The Bland–Altman analysis demonstrated proportional bias in both groups A and B, and the slopes of the regression lines were 0.045 (95% CI, 0.011–0.079) and 0.038 (95% CI, 0.025–0.052), respectively. Interfering peaks were observed in the chromatograms of eight samples in group B, but their effect on the intermethod difference was small. No clinical laboratory test values or concomitant medications were identified as factors affecting the intermethod difference.

Conclusions

The measurement of VRCZ plasma concentration by LM1010 was robust under heterogeneous clinical conditions and was useful for clinical therapeutic drug monitoring of VRCZ.